Syndrome News and Research

RSS

Johnson & Johnson SARS-CoV-2 vaccine shows promise in clinical trials

A new study shows that a single immunization with a low dose of the Ad26.COV2.S vaccine – also known as the ‘Johnson & Johnson vaccine’ – effectively protected against SARS-CoV-2 challenge in rhesus macaques.

2 Feb 2021

ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models

In the absence of effective therapeutics or preventives, vaccines have become the focus of attention. Though over 170 vaccines are in preclinical and about 60 in clinical development, very few are based on plasmid DNA technology. However, a new preprint research paper posted to the bioRxiv* server reports the immunogenicity of a DNA vaccine candidate.

2 Feb 2021

Why SARS-CoV-2 B.1.1.7 is more virulent

A new preprint research paper by scientists from Sweden and India attempts to provide a preliminary answer to these questions using computational modeling. The research, which appears on the bioRxiv* server, predicts increased virulence with the new variant. If validated, this could help public health authorities prepare for new variants' possible impact as they emerge.

2 Feb 2021

Elevated ACE2 and inflammation levels increase risk for pregnant women infected with SARS-CoV-2

Among the hundred million or so cases of coronavirus disease 2019 (COVID-19) that have occurred since the pandemic began, pregnant women have been a conspicuous risk group. However, the exact nature of the risk they and their fetuses face, and the mechanism by which it operates, is far from clear.

2 Feb 2021

Evidence that Long COVID-19 impacts children

The ongoing coronavirus 2019 (COVID-19) pandemic has caused over one hundred million reported infections, with over 2.23 million deaths worldwide. While most cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are asymptomatic or mild, some patients report long-haul symptoms, often severely debilitating in nature. However, it is unclear how many children are affected similarly.

2 Feb 2021

SARS-CoV-2 triggers development of new-onset IgG autoantibodies in hospitalized COVID-19 patients

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent for coronavirus disease 2019 (COVID-19), is associated with several clinical features common in autoimmune diseases as myalgias, arthralgias, fatigue, and rashes. COVID-19 patients also exhibit less common autoimmunity manifestations such as myositis, thrombosis, myocarditis, encephalitis, vasculitis, and arthritis.

1 Feb 2021

Urinary shedding of spike protein in COVID-19 patients

A team of scientists from the United States has recently revealed that about 25% of people with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection develop renal complications and that the viral spike protein can be detected in the urine samples of these patients. The study is currently available on the medRxiv* preprint server.

1 Feb 2021

High national prevalence of SARS-CoV-2 with regional variability in England, REACT-1 survey finds

The REACT-1 survey conducted in the United Kingdom demonstrates a high average prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in England during January 2021. The survey also indicates that a sustained reduction in infection prevalence is urgently needed to avoid burden on healthcare systems and reduce coronavirus disease 2019 (COVID-19)-related mortality.

1 Feb 2021

By July of 2020, 16.8 million people in the US infected with SARS-CoV-2 and didn’t know it

A seroprevalence study of nearly 10,000 people in the United States in the first six months of the COVID-19 pandemic suggests there were at least five people with undiagnosed disease for every case diagnosed.

1 Feb 2021

New platform using green algae tests for SARS-CoV-2 virus

Researchers at the University of California, San Diego, have demonstrated the potential of using green algae to make recombinant viral proteins that could be used in large scale assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the agent that causes coronavirus disease 2019 (COVID-19).

1 Feb 2021

Granulocyte changes could help predict patient outcomes in COVID-19

Researchers in Sweden have provided a comprehensive characterization of circulating granulocytes in people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

1 Feb 2021

Researchers explore rapid outbreak of COVID-19 in U.S. detention facility

To assess the transmission of SARS-CoV-2 in a detention facility experiencing a COVID-19 outbreak, researchers at the U.S. Centers for Disease Control and Prevention (CDC) conducted testing for detained individuals in six quarantined dormitories at various time points.

1 Feb 2021